Moderna's (MRNA) stock has seen significant upswing and recently broke out above the 50-day moving average. The company revealed strong immune response in patients with its updated next-generation COVID shot. Meanwhile, the UK opened Moderna mRNA Vaccine Centre in Oxfordshire and initiated a £50 million Life-Sciences Fund. The company's mRNA-1083 vaccine was compared with Pfizer's dual-target mRNA vaccines for influenza and COVID-19. Following the announcement of a £1 billion UK R&D Investment, Moderna shares went up by 15.8%. Moderna’s promising efficacy results from the mRNA flu vaccine trial were announced.
However, there were also some setbacks. U.S. cancelled a contract with Moderna to develop Bird Flu Vaccine, also the Health and Human services announced the withdrawal of a $590 million contract for Bird Flu. Moreover, Moderna's plans to establish an mRNA manufacturing plant in Japan were scrapped due to an uncertain business environment. Additionally, Moderna's high revenue outlook for 2025 was scaled back due to a vaccine shipment delay in the UK.
Despite these challenges, Moderna has continued to innovate. The company expanded into Oncology with a Pan-Tumor Vaccine. It also announced full approval for COVID-19 Vaccine in Children at increased risk. The company is looking to reduce COVID sales dependency with upcoming product launches.
Moderna MRNA News Analytics from Tue, 07 Jan 2025 08:00:00 GMT to Sat, 04 Oct 2025 04:21:23 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -3
